

# Self-management interventions to reduce urgent healthcare use in patients with asthma: a network meta-analysis

<sup>1\*</sup>Alexander Hodkinson, <sup>1</sup>Peter Bower, <sup>1</sup>Christos Grigoroglou, <sup>1</sup>Salwa S Zghebi, Hilary Pinnock, <sup>1</sup>Evangelos Kontopantelis, <sup>1</sup>Maria Panagioti  
<sup>1</sup>NIHR School for Primary Care Research, Manchester Academic Health Science Centre, University of Manchester, M13 9PL

## Background

- Asthma affects more than 330 million people worldwide, causing 250,000 deaths each year and enormous economic burden.
- International guidelines (NICE & BTS/SIGN) recommend the use of self-management education for treating people with asthma.
- Self-management (SMI) for asthma could involve varying hours of support from healthcare professionals, different delivery modes or multidisciplinary teams.
- We compare and rank the effects of the four models of SMI for managing asthma among adults and children with an aim to guide policy-makers on implementing the most efficient model.

## Methods

We categorised SMIs into four types reflecting varying degree of support by health professionals; a) case management (CM), b) intensive self-management (ISM), c) supported self-management (SSM) and d) pure self-management (PSM) [See handout for full definitions].

Primary outcomes include health care utilisation (HCU) (i.e. hospitalisation/ accident and emergency visit, or any unscheduled visit) and quality of life (QoL).


Analysis was conducted using Bayesian random-effects NMAs and normal likelihood for both outcomes. Models were fit in OpenBugs (version 3.2.3) using uninformative prior distributions. Inconsistency analysis ensured consistency of the network.

Meta-regressions, subgroup analysis (by age) and covariate-adjusted network analyses were performed to assess the effects of pre-specified covariates.

## Results

105 randomised controlled trials (comprising 27,767 participants) between 2000 and 2019 met our inclusion criteria.

Figure A Network of evidence for unscheduled healthcare use



**HCU:** both case-management (SMD=-0.18, 95% CrI: -0.32 to -0.05) and intensive self-management (SMD = -0.30, 95% CrI: -0.46 to -0.15) were significantly better than usual care and other SMIs (figure A)

**QoL:** only intensive self-management (SMD = 0.54, 95% CrI: 0.11 to 0.96) showed a statistically significant increase when compared to usual care

SUCRA ranking indicated intensive self-management as the best model for HCU (97.9%) and for QoL (89.5%) followed by case management. Both intensive self-management and case-management were more effective in the head to-head comparisons for both outcomes (below table).

CM	ISM	SSM	PSM	UCE	UC
-0.02 (-0.64 to 0.61)*	0.50 (-0.17 to 1.17)*	0.93 (0.08 to 1.78)†	0.80 (0.19 to 1.40)†	0.52 (-0.03 to 1.07)*	
0.12 (-0.07 to 0.31)*	ISM	0.52 (-0.04 to 1.09)*	0.95 (0.20 to 1.70)†	0.81 (0.35 to 1.29)*	0.54 (0.11 to 0.96)*
-0.17 (-0.35 to -0.01)*	-0.29 (-0.46 to -0.13)*	SSM	0.43 (-0.39 to 1.25)†	0.29 (-0.24 to 0.85)*	0.02 (-0.49 to 0.52)*
-0.52 (-0.89 to -0.17)†	-0.64 (-1.00 to -0.30)†	-0.35 (-0.70 to -0.01)†	PSM	-0.13 (-0.91 to 0.64)‡	-0.41 (-1.11 to 0.28)*
-0.15 (-0.34 to 0.03)*	-0.27 (-0.43 to -0.12)*	0.02 (-0.12 to 0.16)†	0.37 (0.05 to 0.70)†	UCE	-0.28 (-0.79 to 0.23)*
-0.18 (-0.32 to -0.05)*	-0.30 (-0.46 to -0.15)*	-0.01 (-0.13 to 0.11)*	0.35 (0.007 to 0.69)*	-0.03 (-0.18 to 0.12)*	UC


Light orange: Unscheduled healthcare use; light blue: Quality of life  
Data are SMDs (95% CrIs) in the column-defining treatment compared with the row-defining treatment  
The certainty of the evidence (according to GRADE) was incorporated in this figure by: \*Moderate quality of evidence; †Low quality of evidence; ‡Very low quality of evidence

Statistic	Unadjusted model	Covariate adjusted RE Normal-likelihood model				
		Length of intervention	Healthcare setting	Gender	Age	Asthma severity at baseline
Interaction coefficient, median (95% CrI)	-	-0.10 (-0.46, 0.09)	0.40 (-0.05, 0.85)	-0.15 (-0.51, 0.02)	-0.26 (-0.46, -0.08)	-0.39 (-0.98, -0.06)
DIC difference between adjusted and unadjusted models of the same data	51.84	48.21	55.69	48.15	48.03	46.06
Residual deviance	67.17	63.18	70.84	63.05	55.90	54.52
Heterogeneity SD (median and 95% CrI)	0.15 (0.07, 0.24)	0.14 (0.05, 0.23)	0.18 (0.12, 0.38)	0.14 (0.05, 0.22)	0.13 (0.03, 0.21)	0.07 (0.00, 0.15)
Relative % change in the variance	-	8%	0%	5%	11%	32%
Interaction coefficient, median (95% CrI)	-	0.01 (-0.35, 1.13)	-0.46 (-1.48, 0.09)	0.06 (-0.48, 1.01)	0.13 (-0.05, 0.39)	0.45 (0.09, 0.72)
DIC (difference between adjusted and unadjusted) models of the same data	46.45	45.98	75.09	45.79	45.32	45.21
Residual deviance	78.33	77.95	89.44	74.56	73.73	73.75
Heterogeneity SD (median and 95% CrI)	1.01 (0.84, 1.23)	1.00 (0.80, 1.20)	1.10 (0.94, 1.37)	0.99 (0.81, 1.25)	0.97 (0.79, 1.20)	0.84 (0.61, 1.11)
Relative % change in the variance	-	4%	0%	4%	10%	26%

DIC=deviance information criterion, SD=standard deviation, CrI=credible interval.

- The 'severity at baseline' was the strongest explanation of heterogeneity and inconsistency in meta-regression analyses (above table).
- Excluding studies mainly involving non-severe patients at baseline, resulted in a 32% reduction in heterogeneity for HCU and 26% for QoL.

Figure B: Covariate-adjusted network analysis for asthma severity (Key: S=Severe, NS=non-severe)



Covariate-adjusted NMAs (figure B) showed both ISM (SMD=-0.32, 95% CrI: -0.53, -0.11) and CM (SMD=-0.32, 95% CrI: -0.50, -0.16) as significant for HCU in studies involving patients with more severe symptoms of asthma.

## Conclusions

- This is the largest evidence-base to date by use of network analysis to assess the relative merits of the different SMI models in the treatment of asthma.
- Our findings substantially strengthen the clinical basis for the use of SMIs and particularly intensive self-management as first-line choices for treatment of asthma amongst adults, adolescents and children with asthma
- This analysis contributes a helpful perspective to aid the development of more accurate guidelines for asthma self-management that will help improve the design concepts of new self-management programmes and influence policy-based decisions for clinical practitioners

## References

- Asthma UK. Asthma facts and statistics. Last accessed, 10th December 2018. Available at: <https://www.asthma.org.uk/about/media/facts-and-statistics/>.
- Pinnock, H., et al., Systematic meta-review of supported self-management for asthma: a healthcare perspective. BMC Medicine, 2017. 15(1): p. 64.
- Faltinsen, E.G., et al., Network meta-analysis: the highest level of medical evidence? BMJ Evidence-Based Medicine, 2018. 23(2): p. 56-59.
- Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials [Internet]. London: National Institute for Health and Care Excellence (NICE); 2014 Apr. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK310366/>.
- Panagioti, M., et al., Reducing health care utilisation through self-management interventions (RECURSIVE): a systematic review and meta-analysis. Health services and delivery research, 2014. 2.